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Abstract
Background: Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM)
patients, however, there were a small number of studies written about the results of thalidomide therapy in non-
transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly
diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by
thalidomide maintenance therapy.
Results: Induction regimens with thalidomide and dexamethasone, and the oral combination of melphalan,
prednisolone and thalidomide were administrated in 22 and 16 patients, respectively. The remaining 4 patients
received other thalidomide- containing regimens. Twenty-nine patients received thalidomide as a salvage regimen.
Twenty-three out of 26 patients achieving complete remission (CR) and very good partial remission (VGPR)
received thalidomide maintenance. Of the 41 evaluable patients, median time of treatment was 21 months (3- 45
months), ORR was 92.7% with a 63.4% CR/VGPR. With a median follow up of 23 months, 3-year- PFS and 3-year-OS
were 58.6 and 72.6%, respectively. Median time to progression was 42 months. While 3-year-PFS and 3-year-OS in
non-transplant patients receiving thalidomide maintenance therapy were 67 and 80%, respectively.
Conclusions: Prolonged thalidomide therapy enhanced survival rate and less frequently developed serious toxicity
in non-transplant multiple myeloma patients.
To the editor:
Thalidomide based therapy for multiple myeloma
(MM) improves the response and the complete remis-
sion (CR) rates in previously untreated and relapsed/
refractory MM (overall response rate was 48- 73% with
a 5- 10% CR) [1,2]. In this study, we performed a retro-
spective study of 42 newly diagnosed and relapsed/
refractory MM patients treated with thalidomide based
regimens without upfront ASCT at Ramathibodi Hospi-
tal during January 2005-October 2008. Thirteen and 29
patients were previously untreated and relapsed/refrac-
tory MM, respectively (Table 1). Twenty-two patients
received thalidomide 200 mg/day and oral dexametha-
sone 20- 40 mg/day (d1-4) every 2 weeks, 16 patients
received oral melphalan 4 mg/m
2/day (d1-7), predniso-
lone 40 mg/m
2/day (d1-7) and thalidomide 100 mg/day
every 4 weeks, 3 patients received thalidomide 200-400
mg/day and the remaining 1 patient received thalido-
mide 100 mg/day, pegylated liposomal doxorubicin i.v.
40 mg/m
2/day (d1) and oral dexamethasone 40 mg/day
(d1-4, 9-12) every 4 weeks. Eighty-eight percents (23/26
patients) achieving CR/VGPR (very good partial remis-
sion) received thalidomide maintenance therapy (100-
* Correspondence: niparuckblue@gmail.com
Division of hematology, Department of Medicine, Ramathibodi Hospital,
Mahidol University, Thailand
Niparuck et al. Journal of Hematology Oncology 2010, 3:1
http://www.jhoonline.org/content/3/1/1 JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2010 Niparuck et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.200 mg/day). Aspirin 65- 325 mg/day or warfarin 1.5
mg/day was given to all patients for deep vein thrombo-
sis prophylaxis. Of the 41 evaluable patients, median
treatment period was 21 months (3- 45 m). The ORR
(overall response rate) was 92.7%, with a 63.4% CR/
VGPR. Median number of courses to achieve PR and
CR/VGPR were 4 (range, 2-13) and 6 courses (range, 2-
16), respectively. There was no difference in ORR and
CR between frontline and salvage therapy groups (92.3%
vs 93%) and (39% vs 23%), respectively. The ORR and
CR rate for those treated with thal/dex were slightly
higher than those treated with MPT (95.2% vs 87.5%
and 38% vs 25%). Median follow up was 23 months, 3-
year-OS and 3-year-PFS were 72.6 and 58.6%, respec-
tively. Median TTP was 42 months, non- VGPR/CR
patients had significant poorer PFS by multivariate ana-
lysis (p = 0.01) and non-responders had significant
shorter OS (p = 0.01). In maintenance group, median
treatment duration was 14 months (4-37 m). Three-
year-PFS and 3-year-OS were 67 and 80%, respectively.
Toxicities were constipation (81%), neuropathy (67%),
muscle weakness in the legs (5%), infection (7%) and
thrombosis (5%). New agents for treatment of MM with
no planned ASCT show the CR/VGPR rates of 50- 80%
with a PFS of 2 years [3-5]. The CR/VGPR rates in our
patients were also high that might be associated with a
Table 1 Patients’ characteristics and treatment outcomes of previously untreated and relapsed/refractory multiple
myeloma
ORR CR/VGPR PFS OS
Characteristics Total patients (N = 42) No. of
Patients
%
p-value No. of
patients
p-value HR 95% CI p-value HR 95% CI p-value
Age (years),
median (range)
62,(36-75)
≤ 60 17 15(94) 0.83 9(56.3) 0.45 2.95 0.98-8.81 0.05 0.81 0.09-7.27 0.85
> 60 25 23(92) 17(68)
Sex
Male 21 18(85.7) 0.79 13(65) 0.91 0.77 0.25-2.38 0.65 2.06 0.34-12.68 0.44
Female 21 20(95.2) 14(66.7)
Prior treatment
Yes 29 26(92.6) 0.95 19(67.9) 0.69 3.68 0.91-10.28 0.06 0.87 0.96-7.88 0.9
No 13 12(92.3) 8(61.5)
International
staging system
I, II 8, 18 24(92.3) 0.97 15(57.7) 0.93 6.30 0.73-54.01 0.09 2.22 0.20-24.57 0.51
III 13 12(92.3) 8(61.5)
No data 3
M-protein subtype
IgG, IgA, IgM 23, 8, 1 27(87.1) 0.32 19(61.3) 0.86 3.19 0.64-15.91 0.16 1.21 0.13-11.65 0.87
Kappa, Lamda 3, 6 9(100) 6(66.7)
Unknown type 1
Serum creatinine
level
< 2 mg/dl 34 31(91.2) 0.43 22(64.7) 0.57 0.74 0.08-6.72 0.79 0.03 0.01-856.9 0.50
≥ 2 mg/dl 8 7(100) 4(57.2)
Serum b2 M level,
μg/ml
≤ 5 26 24(92.3) 0.53 17(65.4) 0.79 4.89 0.55-43.88 0.16 1.97 0.18-21.81 0.58
> 5 13 11(84.6) 8(61.5)
No data 3
Response to
treatment
Yes 38 - - - - 0.15 0.04-0.61 0.01 0.03 0.01-0.35 0.01
No 3
CR/VGPR
Yes 26 - - - - 0.14 0.04-0.47 0.01 0.21 0.03-1.48 0.12
No 15
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maintenance in CR/VGPR patients provided impressive
survival benefit. Hence, thalidomide is an effective ther-
apy for MM and prolonged thalidomide use had the
survival benefit and had minimal serious toxicity in
non-transplant MM patients. To date, MM remains
incurable. Novel agents continue to be developed and
are eagerly awaited [5-7].
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